Cisplatin

ATC CODE

  • L01XA01

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

Adjuvant small cell lung cancer.

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 27 November 2008


INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Adjuvant lung cancer.

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 27 November 2008

INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

  • Relapsed metastatic breast cancer (mBC) failing an anthracycline and a taxane

NEMLC RECOMMENDATION

  • Approved
    • To be used with gemcitabine

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 15 September 2016

INDICATIONS AND NEMLC RECOMMENDATIONS 4

INDICATION

  • Radio-sensitizer in cervical cancer

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • None

DATE RATIFIED

  • 6 December 2018

INDICATIONS AND NEMLC RECOMMENDATIONS 5

INDICATION

  • Advanced/Metastatic: Various Cancers

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • 11 July 2019

INDICATIONS AND NEMLC RECOMMENDATIONS 6

INDICATION

  • Adjuvant/Neoadjuvant: various cancers

NEMLC RECOMMENDATION

  • Approved

REVIEW INDICATORS

  • n/a

DATE RATIFIED

  • 11 July 2019